Please fill out the form below and we will gladly respond as soon as possible.
New industry analyses project continued growth in the North America synovial sarcoma treatment market, with a predicted compound annual growth rate (CAGR) of 4.2% from 2026 to 2033. The report reflects increasing momentum in rare cancer research, including advances in targeted therapy, immunotherapy, and precision medicine for synovial sarcoma. What’s Driving Growth in Synovial Sarcoma […]
Advances in cell therapy for synovial sarcoma are creating more treatment options for patients with advanced disease. A recent update from Penn Medicine highlights the growing role of T-cell therapies in treating rare cancers like synovial sarcoma. What Is Afami-cel? Afamitresgene autoleucel (afami-cel) is the first FDA-approved T-cell receptor (TCR) therapy for adults with advanced […]